NCT02504359 - Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2015

Primary Completion Date

September 9, 2020

Study Completion Date

September 9, 2020

Conditions

Plasma Cell LeukemiaRecurrent Plasma Cell Myeloma

Interventions

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic peripheral blood stem cell transplantation

DRUG

Carmustine

Given BEAM chemotherapy

DRUG

Cytarabine

Given BEAM chemotherapy

DRUG

Etoposide

Given BEAM chemotherapy

DRUG

Ixazomib Citrate

Given PO

DRUG

Melphalan

Given BEAM chemotherapy

DRUG

Methotrexate

Given IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic peripheral blood stem cell transplantation

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Tacrolimus

Given IV or PO

Trial Locations (2)

27710

Duke University Medical Center, Durham

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER